Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash: 2019-2025

Historic Change in Cash for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$106.0 million.

  • BridgeBio Pharma's Change in Cash rose 25.16% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 304.04%. This contributed to the annual value of $288.5 million for FY2024, which is 1402.42% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Change in Cash stood at -$106.0 million, which was down 150.88% from $208.4 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Change in Cash registered a high of $275.4 million during Q4 2024, and its lowest value of -$198.0 million during Q3 2021.
  • Over the past 3 years, BridgeBio Pharma's median Change in Cash value was $18.2 million (recorded in 2023), while the average stood at $20.7 million.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 2,548.19% in 2021, then slumped by 269.76% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Change in Cash (Quarterly) stood at $213.3 million in 2021, then slumped by 132.30% to -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then soared by 312.79% to $275.4 million in 2024, then increased by 25.16% to -$106.0 million in 2025.
  • Its Change in Cash stands at -$106.0 million for Q3 2025, versus $208.4 million for Q2 2025 and -$140.5 million for Q1 2025.